HK Stock MarketDetailed Quotes

03681 SINOMAB BIO-B

Watchlist
  • 1.560
  • +0.040+2.63%
Market Closed Mar 28 16:08 CST
1.70BMarket Cap-6341P/E (TTM)

About SINOMAB BIO-B Company

China Antibody Pharmaceutical Co., Ltd. (“China Antibody” or the “Company”, stock code: 3681.HK) focuses on the research, development, manufacture and commercialization of immune-mediated disease therapies. The company focuses on scientific research and development. Its flagship product, SM03, is the world's first potential anti-CD22 monoclonal antibody used to treat rheumatoid arthritis. It has already entered phase III clinical trials for rheumatoid arthritis in China, and has been included in the country's 13th Five-Year New Drug Creation Project. In addition, there are a number of first-in-target (first-in-target) and first-in-class (first-in-class) drugs that are potentially under development. Some are already in the clinical stage. Indications cover diseases such as rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, and asthma that do not meet clinical needs.

Company Profile

Symbol03681
Company NameSINOMAB BIO-B
ISINHK0000544194
Listing Date11/12/2019
Issue Price7.60
Shares Offered182.13M share
Founded04/27/2001
RegistrationHong Kong, China
ChairmanRuian Liang
SecretaryYuyan Zhou
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeRooms 303 and 305-307, 15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
Head Office and Principal Place of BusinessRooms 303 and 305-307, 15 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
Fiscal Year Ends12-31
Employees233
MarketHong Kong motherboard
Phone(852)34269833
Fax(852)34269433
Emailinfo@sinomab.com
Business China Antibody Pharmaceutical Co., Ltd. is a biopharmaceutical company in Hong Kong, China, which specializes in the research, development, manufacture and commercialization of immunological disease therapeutics. The company mainly develops biologics and new chemical entities based on monoclonal antibodies. The company's main product, SM03, is a potential monoclonal antibody for rheumatoid arthritis. The company develops drugs for the treatment of rheumatoid arthritis, systemic lupus erythematosus, asthma, pemphigus, dry skin syndrome, and other immune diseases.

Company Executives

  • Name
  • Position
  • Salary
  • Ruian Liang
  • CEO,Nomination Committee Chairman,Executive Director,Chairman of the Board,Authorized Representative,Remuneration Committee Member
  • --
  • Haigang Chen
  • Non-Executive Director
  • --
  • Xun Dong
  • Non-Executive Director
  • --
  • Wenyi Liu
  • Non-Executive Director
  • --
  • Jianmin Zhang
  • Non-Executive Director
  • --
  • Lei Shi
  • Non-Executive Director
  • --
  • George William Hunter CAUTHERLEY
  • Independent Non-Executive Director,Audit Committee Member
  • --
  • Bingzu Han
  • Independent Non-Executive Director,Nomination Committee Member,Audit Committee Chairman,Remuneration Committee Member
  • --
  • Dylan Carlo TINKER
  • Nomination Committee Member,Independent Non-Executive Director,Audit Committee Member
  • --
  • Shanchun Wang
  • Executive Director,President of China
  • --
  • Zhiming Li
  • Audit Committee Member,Remuneration Committee Chairman,Independent Non-Executive Director
  • --
  • Jianping Hua
  • Authorized Representative,CFO
  • --
  • Minghan You
  • Senior Director (Production)
  • --
  • Junyan Xiao
  • Director (Process Development)
  • --
  • Jiahua Zhang
  • Director (Quality Control)
  • --
  • Lixin Zhang
  • Chief Medical Officer
  • --
  • Yuyan Zhou
  • Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg